Ignite Creation Date:
2024-07-17 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06495905
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-07-11
First Post:
2024-01-24
Brief Title:
Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis
Sponsor:
Beijing Tsinghua Chang Gung Hospital
Organization:
Beijing Tsinghua Chang Gung Hospital
Study Overview
Official Title:
Evaluation of the Effectiveness and Safety of Transbronchoscopic Infusion of Amphotericin B Inhalation of Amphotericin B Transbronchoscopic Debridement Systematic Antifungal Multimodal Treatment of Pulmonary Mucormycosis
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of the effectiveness and safety of transbronchoscopic local precision infusion of amphotericin B transoral nebulized inhalation of amphotericin B transbronchoscopic interventional debridement liposomal amphotericin B posaconazole or Isavuconazole multimodal treatment of pulmonary mucormycosis
Detailed Description:
Key rationale for the treatment of mucormycosis is early surgical intervention including local debridement and removal of infected tissues or organs if possible Systemic antifungal therapy is also necessary for mucormycosis including amphotericin B liposomes and deoxycholates Isavuconazole posaconazole and so on Antifungal drug therapy has a mortality rate of up to 40 which can be reduced to 23 when combined with surgical treatment However some patients who are unable to tolerate surgical procedures on the chest when in bad condition especially patients with hematological malignancies undergoing hematopoietic stem cell transplantation are susceptible to multiple mucormycosis of the lungs and the mortality rate of untreated systemically disseminated mucormycosis infections is high at 80 Isavuconazole so we aim to explore the multimodal treatment of liposomal amphotericin B posaconazole or esaconazole transbronchoscopic localized precise instillation of amphotericin B oral nebulized inhalation of amphotericin B transbronchoscopic interventional debridement to alleviate the pulmonary mucormycosis in chest imaging and reduce the mortality rate of patients with mucormycosis infection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None